Glenmark receives U.S. FDA approval to expand the use of RYALTRIS Nasal Spray for Children aged 6 to less than 12 years

Glenmark received U.S. FDA approval to expand RYALTRIS nasal spray use to children aged 6 to less than 12 years for Seasonal Allergic Rhinitis treatment. - Approval extends RYALTRIS use to younger pediatric patients in the U.S. - Supported by Phase 3 study showing symptom improvement and good tolerance. - Strengthens Glenmark's U.S. respiratory portfolio after direct commercialization transition. - RYALTRIS now approved in 56 countries with recent launches in 11 new markets.